Ajanta Pharmaceuticals Ltd. (AJANTPHARM) fundamentals
Ajanta Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AJANTPHARM (ISIN INE031B01049). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Ajanta Pharmaceuticals Ltd. does
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Valuation and market data
| Last close | ₹3381.00 |
|---|---|
| Market capitalisation | ₹42,237 crore |
| Enterprise value | ₹42,342 crore |
| P/E (TTM) | 40.00 |
| Price to book | 9.33 |
| Price to sales (TTM) | 4.24 |
| Book value per share | ₹362.38 |
| Dividend yield | 177.46% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon May 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹5,625 crore | ₹1,378 crore | ₹1,056 crore | 84.53 |
| Mar 2025 | ₹4,743 crore | ₹1,189 crore | ₹920 crore | 73.56 |
| Mar 2024 | ₹4,293 crore | ₹1,114 crore | ₹816 crore | 64.82 |
| Mar 2023 | ₹3,841 crore | ₹745 crore | ₹588 crore | 45.89 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 63.5% |
|---|---|
| Foreign institutions (FII) | 7.6% |
| Mutual funds | 17.9% |
| Other domestic institutions | 4.0% |
| Retail and others | 7.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.